call 1800 257 600 email [email protected]

Gorlin Syndrome

Gorlin syndrome, also known as Gorlin-Goltz syndrome, basal cell nevus syndrome or nevoid basal cell carcinoma syndrome, is a rare genetic condition that is characterised by skeletal abnormalities, cysts on the jaw and a predisposition to malignancy, most notably basal cell carcinoma (BCC).

Familial cancer syndromes, also known as hereditary cancer syndromes, are rare conditions that cause an increased risk of cancer as the result of inherited genetic mutations in certain cancer-related genes. They can affect both adults and children, however they generally develop in people at a younger age than normal. While familial cancer syndromes are not classified as cancer, they are equally as severe and can be life-threatening as they are associated with the development of various tumours throughout the body. Having a familial cancer syndrome does not guarantee the development of cancer, however the risk of developing cancer is higher than those who do not have a familial cancer syndrome.

Gorlin syndrome is generally diagnosed equally among the sexes, and is often diagnosed before the age of 30. However, anyone can develop this disease.

Gorlin syndrome is most commonly associated with the development of basal cell carcinomas, however it has also been linked to other types of tumours. Some examples include:

Treatment

When cancers are detected, they are staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you. However, each patient with Gorlin syndrome will present with a unique disease behaviour, with varying tumour locations and symptoms. As such, there is no one treatment method that will work for everyone, and there is no standard staging system for this disease. Instead of staging and grading, your doctor will recommend a treatment plan based on the following factors:

  • Type of tumours present.
  • Whether the tumours are malignant (cancerous) or benign (non-cancerous).
  • Tumour location.
  • Whether or not malignant tumours have metastasised.
  • Your age.
  • General health.
  • Your treatment preferences.

Your doctor may also recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. They will then discuss the most appropriate treatment option for you.

Treatment options for tumours associated with Gorlin syndrome may include:

  • Surgery to remove as much of the tumour(s) as possible – these will vary based on tumour type and location.
  • Chemotherapy.
  • Cryotherapy.
  • Photodynamic therapy.
  • Clinical trials.
  • Palliative care.

Patients with Gorlin syndrome may be hypersensitive to radiation and radiation therapy may increase the risk of developing other skin cancers. As such, doctors may not recommend this treatment.

Cancer Screening

Once a diagnosis of Gorlin syndrome has been confirmed, implementing a targeted screening plan becomes essential due to the increased risk of developing certain cancers.  The content of this plan will vary from person to person based on the genetic mutation involved, your family’s history of cancer and the types of cancers that may be present. It will also outline the routine tests you should have and how regularly you should have them.  Some recommendations for Gorlin syndrome may include:

  • Annual physical examinations.
  • Brain MRI every six months for children under age three, then annually until age eight.
  • Cardiac ultrasounds in children.
  • Annual x-ray of the jaw.
  • Abdominal and pelvic ultrasounds in females starting at puberty.
  • Skin examinations every 2-3 months for adults.

Screening options for Gorlin syndrome may evolve as new technologies are developed and our understanding of the condition grows. It is essential to discuss your individual circumstances with your healthcare team to determine the most appropriate screening plan for you.

Risk factors

Gorlin syndrome is caused by a genetic mutation in one of the following genes:

  • PTCH1.
  • PTCH2.
  • SUFU.

PTCH1 and PTCH2 are tumour suppressor genes, which act to inhibit cell growth to prevent overproduction of cells and the development of tumours. The SUFU is a negative regulator of the Hedgehog signalling pathway, which is essential for healthy embryonic/fetal development.

Gorlin syndrome is an autosomal dominant disease, which means that you have a 50% chance of developing the condition if one of your parents carries the mutation.

Symptoms

The symptoms of Gorlin syndrome often vary by the type(s) of tumours present. General symptoms of Gorlin syndrome may include:

  • Development of two or more BCCs before the age of 20.
  • Cysts in the jaw.
  • Pits in the palms of the hand and soles of feet.
  • Macrocephaly.
  • Enlarged jaw.
  • Abnormally wide base of the nose.
  • Unusually prominent forehead.
  • Having extra fingers and/or toes.
  • Fused fingers and/or toes.
  • Funnel chest.
  • Pigeon chest.
  • Ocular abnormalities, such as:
    • Scarring of one or both corneas.
    • Cataracts.
    • Glaucoma.
    • Eyes that do not align with each other.
    • Retinal pigmentation.
    • Blindness.
  • Calcification of falx cerebri (a part of the brain).
  • Gynaecomastia.
  • Hypogonadism in males.
  • Bicornuate (heart-shaped) uterus.
  • Cleft lip and/or palate.
  • High arched palate.
  • Intellectual impairment.

Symptoms related to specific tumours can be found on our knowledgebase.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have tumours associated with Gorlin syndrome, they may order some of the following tests to confirm the diagnosis and refer you to a specialist for treatment. The tests required for diagnosis will often vary based on the symptoms present, and where the tumour(s) are suspected to be located.

  • Physical examination.
  • Genetic testing.
  • Neurological examination.
  • Blood tests.
  • Imaging tests, potentially including:
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • X-ray.
    • Ultrasound.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.